|
|
|||||||||||||||||||||||||||
|
Synta Pharmaceuticals Corp (SNTA) Synta Pharmaceuticals is a biopharmaceutical company focused on research, development and commercialization of oncology medicines for cancer patients. Co.'s lead oncology drug candidate, ganetespib, a heat shock protein 90 (Hsp90) inhibitor, is being evaluated in several large randomized clinical trials including GALAXY-2, a pivotal Phase 3 trial in non-small cell lung cancer, as well as in breast cancer, ovarian cancer and acute myeloid leukemia. Co. is also developing several candidates from its proprietary Hsp90 inhibitor Drug Conjugate program, which utilizes the preferential accumulation of Hsp90 inhibitors in tumors to selectively deliver a range of anti-cancer payloads.
|
|
|||||||||||||||||||||||||||
Free SNTA Email Alerts:
Synta Pharmaceuticals Corp (SNTA) Page | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.